Joséphine Carpentier,Iuliia Pavlyk,Uma Mukherjee et al.
Joséphine Carpentier et al.
Arginine deprivation has gained increasing traction as a novel and safe antimetabolite strategy for the treatment of several hard-to-treat cancers characterised by a critical dependency on arginine. Small cell lung cancer (SCLC) displays ma...
Deconstructing ADAURA. It is Not Yet Time to Forgo Platinum-based Adjuvant Chemotherapy in Resected Early Stage (IB-IIIA) EGFR-mutant NSCLC [0.03%]
解析ADAURA研究：在EGFR突变型II至IIIA期非小细胞肺癌患者中，目前还不能放弃以铂类为基础的辅助化疗
Danielle Brazel,Misako Nagasaka
Danielle Brazel
Recently, the ADAURA study demonstrated statistically significant improved disease-free survival (DFS) with adjuvant osimertinib in patients with resected stage IB-IIIA non-small cell lung cancer (NSCLC) harboring an epidermal growth factor...
Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation [0.03%]
tepotinib和capmatinib治疗非小细胞肺癌MET外显子14跳跃突变患者的疗效分析
Danielle Brazel,Shannon Zhang,Misako Nagasaka
Danielle Brazel
Mesenchymal-epithelial transition (MET) receptor tyrosine kinase is overexpressed, amplified, or mutated in 1-20% of NSCLC. MET dysregulation is associated with a poor prognosis. Recently, development of targeted therapies against MET exon ...
Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib [0.03%]
ADAURA研究启示：采用辅助奥希替尼时代，是否可以摒弃EGFR突变阳性II-IIIa期NSCLC（含Ib）的以铂类为基础的化疗（伴有RB基因改变者未确定）
Shannon S Zhang,Sai-Hong Ignatius Ou
Shannon S Zhang
Adjuvant cisplatin-based chemotherapy is considered the standard of care for resected stage IB (tumor ≥ 4m)-IIIA non-small cell lung cancer (NSCLC). The ADAURA trial is a randomized placebo-controlled Phase III trial that demonstrated stat...
ORIENT-31 as the Sakigake "Charging Samurai" Born of IMpower150 but Will MARIPOSA-2 IMPRESS in the "Meiji Modernization" of Post-3G EGFR TKI Progression? [0.03%]
ORIENT-31作为Sakigake“蓄势待发的武士”应运而生，基于IMpower150模式，MARIPOSA-2研究能否在三代EGFR-TKI经治人群这一“明治维新”中大放异彩？
Misako Nagasaka,Sai-Hong Ignatius Ou
Misako Nagasaka
Tyrosine kinase inhibitors (TKIs) have become the preferred first line therapy for those patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. Given superior progression free survival ...
An Update on Emerging Therapeutic Options for Malignant Pleural Mesothelioma [0.03%]
恶性胸膜间皮瘤的新兴治疗选项最新进展
Alexander Davis,Helen Ke,Steven Kao et al.
Alexander Davis et al.
The treatment paradigm for malignant pleural mesothelioma (MPM) has changed little in the last 18 years. Radical intent treatment, consisting of surgical resection, radiotherapy and chemotherapy, has been offered to a highly select few; how...
The Role of Whole Exome Sequencing in Distinguishing Primary and Secondary Lung Cancers [0.03%]
全外显子测序在区分原发性和继发性肺癌中的作用
Natalie I Vokes,Jianjun Zhang
Natalie I Vokes
Non-small cell lung cancer (NSCLC) that presents with multiple lung tumors (MLTs) poses a challenge to accurate staging and prognosis. MLTs that arise as clonally related secondary metastases from a common primary are higher stage and often...
Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer [0.03%]
Amivantamab(JNJ-61186372)在EGFR外显子20插入突变的非小细胞肺癌中的研究进展
Danielle Brazel,Misako Nagasaka
Danielle Brazel
Non-small cell lung cancer (NSCLC) patients demonstrating sensitizing oncogenic driver mutations have derived clinical benefit from targeted therapy. EGFR mutations constitutively activate the signaling pathway, leading to prosurvival and a...
Orla Fitzpatrick,Jarushka Naidoo
Orla Fitzpatrick
Immunocheckpoint inhibitors (ICIs) have altered the treatment landscape of a wide range of malignancies, including non-small cell lung cancer (NSCLC). This class of agents inhibits the interaction between PD1 and PDL1, and was shown to be e...
Spotlight on Sotorasib (AMG 510) for KRAS G12C Positive Non-Small Cell Lung Cancer [0.03%]
索托拉西布(Sotorasib, AMG 510)治疗KRAS G12C阳性非小细胞肺癌的亮点
Shannon S Zhang,Misako Nagasaka
Shannon S Zhang
Mutations in codon 12 of KRAS have been identified in 13% of non-small cell lung cancer patients. Developing targeted therapies against KRASG12C mutation has proven to be challenging due to the abundance of GTP in the cytoplasm, rapid hydro...